Article

Not Enough Cancer Drugs, Too Many Price Controls

Cancer patients face daunting challenges, including side effects of treatment, impact on family life and work disruptions. They now face another problem: shortages of vital drugs.

Imagine an oncologist talking to his patient: Everything is going well with your treatment, he says, but one of the drugs you've been receiving is unavailable. There's a substitute—sort of. Your Medicare copayment for the drug we've been using is $9. Now it will cost you $520 each time the substitute is given.

Read the full story: http://on.wsj.com/SQoOVB

Source: The Wall Street Journal

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo